Sanfilippo Syndrome (Mucopolysaccharidosis Type III) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Sanfilippo Syndrome, also known as Mucopolysaccharidosis Type III is an autosomal recessive disease with four subtypes, A, B, C, and D, with deficiencies in heparan-N-sulfatase, α-N-acetylglucosaminidase, α-glucosaminide acetyltransferase, and N-acetylglucosamine-6-sulfatase, respectively, all leading to the accumulation of HS. It primarily affects the central nervous system with mild somatic effects; classic findings include hyperactivity and neurocognitive-behavioural issues. Patients are often diagnosed when language delay, behavioural issues, and hyperactivity are noticed between the ages of 2 and 6 years old. By the age of ten, up to 60% of MPS III patients have seizures. After the first decade of life, insidious progressive gait disorders and pyramidal signs often lead to a vegetative state and death by the early 30s. Retinopathy is the most common ocular condition seen in Sanfilippo syndrome. Aggregations of heparan sulfate within the retinal pigment epithelial cells and the photoreceptor matrix cause progressive photoreceptor loss, dysfunction, and retinal degeneration.
- The incidence of Sanfilippo Syndrome (Mucopolysaccharidosis Type III) varies between 1 to 2 cases in every 100,000 live births.
Thelansis’s “Sanfilippo Syndrome (Mucopolysaccharidosis Type III) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sanfilippo Syndrome (Mucopolysaccharidosis Type III) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Sanfilippo Syndrome (Mucopolysaccharidosis Type III) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Sanfilippo Syndrome (Mucopolysaccharidosis Type III) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
